Navigation Links
Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
Date:11/26/2007

NBA, NFL and PGA Players Purchase SURGEX(TM) as Millennium Launches

http://www.surgexsports.com

BASKING RIDGE, N.J., Nov. 26 /PRNewswire/ -- Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements for the medical market, announced today the launch of their advanced sports nutritional product, SURGEX(TM) (http://www.surgexsports.com). SURGEX(TM) was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States. The proprietary formula intends to meet the growing demand of elite level professional and amateur athletes and their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

SURGEX(TM) has already caught the attention of numerous professional and collegiate athletes and teams. Many of which have made the switch to using SURGEX(TM) exclusively. Mike Curtis, current Strength and Conditioning Coach for the Memphis Grizzlies, uses SURGEX(TM) exclusively with the athletes he trains. Mr. Curtis adds, "The athletes I work with are some of the most well conditioned in the world. They require sophisticated nutritional support to aid in their recovery from intense year round training. My athletes are committed to finding ways to enhance their recovery and I believe SURGEX(TM) has played an integral role in that process."

SURGEX(TM) constitutes a blend of extended release proteins, anti- oxidants, amino acids and whole food calories to meet the multi-nutritional needs of Strength, Speed, and Endurance athletes. It works to counteract the stress that exercise puts on the body through an all-in-one nutritional supplement. During intense training, muscles incur cell damage and fatigue. The body tries to recover itself by automatically rebuilding that damage over time. If the muscles are re-trained before they have fully recovered, muscle repair and development can be inhibited, resulting in potential damage and decreased physical performance.

In double blind placebo controlled trials at the Rutgers University Human Performance Lab SURGEX(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise by improving peak power outputs, lowering oxidative stress/inflammatory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as the lessening of free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified to contain no banned substances.

Supporting the launch is the debut of a state of the art website surgexsports.com. The state of the art site will provide a plethora of information on the science behind proper recovery from intense training and Millennium's study results supporting its claims for improving strength, endurance, oxidative stress markers and faster recovery. Visitors will also be able to order SURGEX(TM) for individual or team use on the site's online store.

"This is clearly a multibillion dollar industry worldwide and to leverage our proven, patent protected formulas, in a global sports market place will significantly enhance share holder value. With over twenty professional basketball players currently using our product, some for over a year, we believe that this will ignite a strong demand across numerous sports channels worldwide," said Mark Mirken, Chief Operating Officer of Millennium Biotechnologies.

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a SURGEX(TM) sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immunocompromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").


'/>"/>
SOURCE Millennium Biotechnologies Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
2. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
3. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Life Sciences Leader Joins Millennium Board of Directors
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
10. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
11. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Franz Inc ., the leading ... , has been named a ‘Champion’ by Bloor Research in its recent Graph ... in its class, and, thanks to Gruff, it was rated as the easiest product ...
(Date:3/28/2017)... ... March 28, 2017 , ... Ecovia Renewables, Inc. announced ... (SBIR) grant from the National Science Foundation (NSF). Under the award , ... suite of BioGel™ biopolymer materials for hygiene applications, particularly for use in the ...
(Date:3/28/2017)... March 28, 2017 Summary This ... Enzo Biochem and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/28/2017)... March 28, 2017 Volition America, Inc., a wholly-owned ... the engagement of Deborah Vollmer Dahlke , DrPH, CEO ... Dr. Vollmer Dahlke,s role will be to assist ... State of Texas and elsewhere in ... Dahlke has significant experience over the past six years, ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
Breaking Biology News(10 mins):